Interested in Connecting? Please contact: Alexander Sigalov President and CEO firstname.lastname@example.org
Message the company or request a 1:1 meeting here.
Massachusetts-based preclinical biotech SignaBlok develops a breakthrough therapy that addresses a $10B+ unmet need in the prevention and treatment of retinal neovascularization (RNV), a determinant cause of vision loss in retinopathy of prematurity (ROP), diabetic retinopathy (DR) and retinal vein occlusion. 16,000 of premature infants in US are affected by ROP annually and 7.7 million Americans over 40 years have DR. Few available treatment options (surgery, laser treatment and eye injections of anti-VEGF drugs) are harmful, do not cure, have a high risk of complications and often ineffective. Successfully preclinically tested and validated in preventative and therapeutic regimens, SignaBlok’s well-tolerable TREM-1 therapy GF9 is supported by world-renowned experts and creates hope in prevention and treatment of blindness due to RNV.